921605-76-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-(2-(Trifluoromethyl)phenoxy)piperidine-1-carboxylate is utilized as a building block in the synthesis of pharmaceutical products. Its unique structural features and the presence of the tert-butyl ester group make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, tert-butyl 4-(2-(Trifluoromethyl)phenoxy)piperidine-1-carboxylate serves as a key building block for the synthesis of various agrochemical products. Its stability and ability to alter the physicochemical properties of molecules contribute to its effectiveness in this field.
Used in Research and Development:
Due to its unique structural features, tert-butyl 4-(2-(Trifluoromethyl)phenoxy)piperidine-1-carboxylate also holds potential in the research and development of new drugs and agrochemicals. Its versatility and stability make it a promising candidate for further exploration and innovation in these industries.

InChI:InChI=1/C17H22F3NO3/c1-16(2,3)24-15(22)21-10-8-12(9-11-21)23-14-7-5-4-6-13(14)17(18,19)20/h4-7,12H,8-11H2,1-3H3

Upstream product

• 444-30-4 2-(trifluoromethyl)phenol 
• 603-35-0 triphenylphosphine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 824390-04-7 4-(2-(trifluoromethyl)phenoxy)piperidine 
• 823782-74-7 4-[2-(trifluoromethyl)phenoxy]piperidine hydrochloride 
• 916889-35-5 5-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazole-2-carbonitrile 
• 957941-07-0 4-{4-[2-(trifluromethyl)phenoxy]piperidin-1-yl}benzohydrazide 
• 957941-15-0 methyl 3-oxo-3-[2-(4-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}benzoyl)hydrazino]propanoate 
• 1085784-05-9 methyl 6-({[(4-amino-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-1,3-thiazol-5-yl)carbonyl]amino}carbonyl)nicotinate 
• 1085784-14-0 5-({[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino}methyl)-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one 
• 1085784-06-0 methyl 6-(7-oxo-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-6,7-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl)nicotinate 
• 1085783-87-4 5-[(pyridin-2-ylthio)methyl]-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one 
• 1085784-48-0 ethyl ({2-[4-(2-trifluoromethylphenoxy)piperidin-1-yl]-5-methyl[1,3]thiazolo[4,5-d]pyrimidin-7-yl}oxy)acetate 
• 1085783-85-2 3-(7-oxo-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-6,7-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl)propanoic acid 
• 1085783-84-1 methyl 3-(7-oxo-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-6,7-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl)propanoate 
• 1085784-46-8 ({2-[4-(2-trifluoromethylphenoxy)piperidin-1-yl]-5-methyl[1,3]thiazolo[4,5-d]pyrimidin-7-yl}oxy)acetic acid 
• 1085783-83-0 methyl 7-oxo-2-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-6,7-dihydro[1,3]-thiazolo[4,5-d]pyrimidine-5-carboxylate 

Relevant academic research and scientific papers

BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES

The present invention provides a compound having the structure: Formula (I) wherein X is CR6 or N; R1, R2, R3, R4, and R6 are each independently -H, -F, -Cl, -Br, -I, -NO2, -CN, -CF3, -CF2H, -OCF3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), -OH, -OAc, -0-(alkyl), -0-(alkenyl), -0-(alkynyl), -0-(aryl), -O- (heteroaryl), -SH, -S-(alkyl), -S-(alkenyl), -S-(alkynyl), -S- (aryl), -S-(heteroaryl), -NH2, -NH-(alkyl), -NH-(alkenyl), -NH- (alkynyl), -NH-(aryl), -NH-(heteroaryl), -C(O)R7, -S(O)R7, SO2R7, -NHSO2R7, -OC(O)R7, -SC(O)R7, -NHC(O)R8 or -NHC(S)R8, wherein R7 is, H, -(alkyl), -OH, -O(alkyl), -NH2, -NH(alkyl) or -N(alkyl)2, and wherein R6 is, -(alkyl), -O-(alkyl), -NH2, -NH(alkyl) or N(alkyl)2; Y is O, S, Ν, ΝΗ, or a bond; Z is O, S, N, NH, (CH2)O, or a bond; R5 is H, OH, halogen, alkyl, or R5 is (CH2)P and is bound to Y when Y is N to form a ring together with Z; o and p are independently 0, 1, 2, or 3; m and n are independently 0, 1, 2, 3, or 4; A, C, and D are each independently N or CR9; R9 is H, halogen, -OH, alkyl, cycloalkyl, cycloalkylalkyl, -O-(alkyl), -S-(alkyl), -NH2, -NH(alkyl), NH(alkyl)2, -CO2H, -CO(O-alkyl); B and E are N, CR9, or CFG wherein at least one of B or E is CFG; F is absent or present, and when present is Formula (II), Formula (III) G is H, substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, aryl, heteroaryl, alkyl, cycloalkyl, cycloalkylalkyl, CO2H, COOR10, OH, OR10, NH2, NHR10, NR10R11, SO2 (alkyl), SO2 (cycloalkyl), SO2(cycloalkylalkyl), CH2NHR10, CH2NR10R11, or CH2COOR10, wherein each R10 R11 are each independently H, alkyl, cycloalkyl, -C(O)-alkyl, -C(O)-cycloalkyl,-C(O)OH, -C(O)-O- alkyl, -C(O)-O-cycloalkyl, -C(O)NH2, -C(O)NH(alkyl), - C(O)NH(cycloalkyl), -C(O)N(alkyl)2, -CH2NH(alkyl), -CH2COOH, - SO2CH3, -OH, -O(alkyl), -NH2, -NH(alkyl), -N(alkyl)2, or a pharmaceutically acceptable salt thereof.

Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities

Accumulation of cytotoxic lipofuscin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis. Retinal bisretinoid synthesis depends on the influx of serum all-trans-retinol (1) delivered via a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. We previously identified selective RBP4 antagonists that dissociate circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis. However, the release of TTR by selective RBP4 antagonists may be associated with TTR tetramer destabilization and, potentially, TTR amyloid formation. We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabilizers. Standout analogue (±)-44 possesses suitable potency for both targets, significantly lowers mouse plasma RBP4 levels, and prevents TTR aggregation in a gel-based assay. This new class of bispecific compounds may be especially important as a therapy for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease associated with wild-type TTR misfolding.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.

NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS

The present invention relates to compounds having general formula I characterised in that wherein in particular: R1 represents one or a plurality of groups such as: trifluoromethyl, halogen such as F, Cl, Br, methyl, nitro. R represents nitroge

DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS

The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: -R1 represents one or more groups such as: trif luoromethyl, halogen such as F, C1, -when n=m=1, W represents CH then Y represents oxygen, -U represents: ? either - (C=O) CH2NH- and is branched at position 4 of pyridazinone, then R2 represents H, ? or -(C=O)NH- and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, - R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enyzme inhibitors for the treatment of obesitz, tzpe-2 diabetes and lipid disorders.

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.

BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis

Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis